IP Library › Granted Patent US 9,393,252
Granted Patent B2
US 9,393,252 · App. 13/795,186 · Granted Jul 19, 2016

Aromatic carboxylic acids in combination with aromatic hydroxyamides for inactivating non-enveloped viruses

Inventors: Daniel E. Pedersen (Cottage Grove, MN); Hilina Emiru (Rosemount, MN); Carter Martin Silvernail (Burnsville, MN)
Assignee: ECOLAB USA INC.
A61K31/609A01N31/02A01N37/40A61K31/045A61K31/192A61K31/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,393,252
App. No.
13/795,186
Granted
Jul 19, 2016
Kind
B2
Abstract

The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alcohol and a synergistic combination of an aromatic carboxylic acid and an aromatic hydroxyamide. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.

Claims (27)

1. An antiviral composition having activity against non-enveloped viruses comprising:

salicylic acid in an amount between about 1 weight percent and about 2 weight percent of the composition; salicylamide in an amount of about 2 weight percent of the composition;

a C 1 -C 6 linear and/or branched alcohol; and

water;

wherein said antiviral composition has activity against non-enveloped viruses.

2. The antiviral composition of claim 1 , wherein said antiviral composition causes a greater than 3 log reduction in non-enveloped virus populations in less than one minute.

3. The antiviral composition of claim 1 , wherein said alcohol is ethanol, isopropanol or n-propanol or mixtures thereof.

4. The antiviral composition of claim 1 , wherein said salicylic acid is present in an amount of about 1 weight percent of said antiviral composition.

5. The antiviral composition of claim 1 , wherein said salicylic acid is present in an amount of about 1.5 weight percent of said composition.

6. The antiviral composition of claim 1 , wherein said antiviral composition has a pH of from about 1.0 to about 6.8.

7. The antiviral composition of claim 1 , further comprising a sulfonated surfactant.

8. The antiviral composition of claim 1 , wherein said antiviral composition provides virucidal activity of greater than 3 logs in 30 seconds and further provides bactericidal activity of greater than 3 logs in 30 seconds.

9. A method of reducing norovirus activity comprising: contacting a surface with the antiviral composition according to claim 1 .

10. The method of claim 9 , wherein said surface is skin.

11. The method of claim 9 , wherein said surface is a hard surface.

12. An antiviral diluted solution having virucidal activity against non-enveloped viruses comprising:

from about 40 weight percent to about 90 weight percent of a C 1 -C 6 linear and/or branched alcohol;

salicylic acid in an amount from about 1 weight percent to about 2 weight percent of the solution;

salicylamide in an amount of about 1 weight percent of the solution;

and water;

wherein said antiviral diluted solution has activity against non-enveloped virus.

13. The antiviral diluted solution of claim 12 , wherein said salicylic acid is about 1 weight percent of the solution.

14. The antiviral diluted solution of claim 12 , wherein said salicylic acid is about 1.5 weight percent of said solution.

15. The antiviral diluted solution of claim 12 , further comprising a sulfonated surfactant.

16. The antiviral diluted solution of claim 12 , wherein said solution further comprising benzoic acid, derivatives of benzoic acid, and/or derivatives of salicylic acid.

17. The antiviral composition of claim 1 , wherein said composition has antiviral activity against a norovirus.

18. The antiviral diluted solution of claim 12 , wherein said solution has antiviral activity against a norovirus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2013
From: PEDERSEN, DANIEL E.; EMIRU, HILINA; SILVERNAIL, CARTER MARTIN
To: ECOLAB USA INC.
Reel/Frame 030207/0762 →
Continuity (1)
Related Publication 20140274973A1 · Sep 18, 2014